Study on the Mechanism of CCN2 Promoting Sorafenib Resistance in HCC and Its Combined Intervention Strategy
These results not only elucidate a novel CCN2/FAK/YAP/c-Met axis in sorafenib resistance but also provide a mechanistic rationale for dual-targeting strategies to improve outcomes in advanced HCC.
Authors
- Ke-Jun Liu (ORCID: https://orcid.org/0000-0001-5770-7865)
- Yongxue Lv (ORCID: https://orcid.org/0000-0002-9095-0469)
- Bendong Chen (ORCID: https://orcid.org/0009-0001-5618-6962)
- Yang Bu (ORCID: https://orcid.org/0000-0003-1219-997X)
- Lei Cui (ORCID: https://orcid.org/0009-0007-4172-2092)
- Junhao Liu (ORCID: https://orcid.org/0009-0003-2705-5124)
Institutions
- Ningxia Medical University (CN)
- Ningxia Medical University General Hospital (CN)
Publication Details
- Journal
- Frontiers in Bioscience-Landmark
- Published
- 2025-10-31
- DOI
- https://doi.org/10.31083/fbl45454
- Primary Topic
- Connective Tissue Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Ningxia Province